AAAAI 2021 Annual Meeting
AAAAI Annual Meeting

Sponsored Programs

 

These programs are not sponsored or programmed by the AAAAI. Please also be aware that these programs relate to the 2020 AAAAI Annual Meeting, which was cancelled due to the COVID-19 pandemic. They are separated by CME and Non-CME programs.

A number of sponsored programs that were originally scheduled as Non-CME Educational Programs during the 2020 AAAAI Annual Meeting have been or will be converted into virtual formats. Some will be live virtual events, while others will be recordings that you can access at your convenience, and some will offer CME by accredited providers other than the AAAAI.

Please see below for a listing of these programs with further details on how to participate. The page will be updated as more programs are available.

______________________________________________________________________________

CME Programs

______________________________________________________________________________

Exploring the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

An Interactive Live CME Webcast and Case Simulation
Choose from 3 different dates and times!

Thursday, September 17, 2020
8:00 PM – 9:00 PM (ET)

Tuesday, September 29, 2020
9:00 PM – 10:00 PM (ET)

Until recently, treatment options for severe asthma with an eosinophilic phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome were limited mostly to immunosuppression with oral corticosteroids (OCS) or other systemic agents. An expanding understanding of the pathophysiology of these diseases has led to the identification of newer therapeutic targets and more selective and better tolerated treatments for eosinophil reduction.

This interactive webcast will review strategies for recognizing these phenotypes of severe eosinophilic diseases of the lungs and help the clinician better navigate available treatments in order to improve symptoms, lighten the disease burden, and reduce exacerbations and OCS reliance for patients with severe asthma and associated eosinophil-mediated conditions.  

For complete details or to register, visit: www.integrityce.com/asthma

This CME activity is provided by Integrity Continuing Education.
This activity is supported by an educational grant from GlaxoSmithKline.

______________________________________________________________________________

CME/CE Online Activity

AIRING IT OUT: A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyps

View Here: https://www.exchangecme.com/AiringItOut2020    

Faculty: Joseph K. Han, MD; John J. Oppenheimer, MD; Reynold A. Panettieri, Jr, MD

This Case-in-Point™ online activity focuses on the management of moderate-to-severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Each segment of the activity will open with a brief multimedia presentation of a clinical case, highlighting the patient’s unique past medical history, current management challenges, and persistent, daily burdens. Expert faculty will guide learners through each case, sharing relevant guideline recommendations, published data, and clinical insights.

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, and jointly provided by Postgraduate Institute for Medicine (PIM) and Integritas Communications.

______________________________________________________________________________

A Virtual Reality View: New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This online activity will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

View now: https://www.medlearninggroup.com/a-virtual-reality-view-new-approaches-to-the-diagnosis-and-treatment-of-pediatric-and-adolescent-patients-with-moderate-to-severe-atopic-dermatitis/

______________________________________________________________________________

Non-CME Programs

______________________________________________________________________________

Understanding Chronic Cough
Sponsored by Merck

Chronic cough is often associated with underlying conditions, such as asthma, gastroesophageal reflux disease, nonasthmatic eosinophilic bronchitis, and upper-airway cough syndrome.  In some patients with chronic cough, treatment of these underlying conditions does not resolve the cough (Refractory Chronic Cough, RCC), or none of these underlying conditions are present (Unexplained Chronic Cough, UCC).
Please join Michael S. Blaiss, MD, Clinical Professor of Pediatrics at Medical College of Georgia Augusta, Georgia, Executive Medical Director of the American College of Allergy, Asthma and Immunology, for this non-CME program to learn more about Chronic Cough.  Topics will include:
•    The disease burden and unmet need in management of chronic cough
•    Mechanisms of the disease
•    Classification and clinical assessment of chronic cough

You will have two opportunities to participate in this live Program:

Wednesday, October 14, 12:15-1:00 PM ET
(11:15-12:00 PM CT, 10:15-11:00 AM MT, 9:15-10:00 AM PT)

Wednesday, October 28, 5:15-6:00 PM ET
(4:15-5:00 PM CT, 3:15-4:00 PM MT, 2:15-3:00 PM PT)

Register at: https://webinars.on24.com/merck/chroniccough

______________________________________________________________________________

On Demand Videos
Available Now

Sponsored by GSK

Please follow the link below for 3 brief educational videos you may watch on demand anytime.

•    The Role of Eosinophils and Their Potential Heterogeneity in Airways Disease
Medical experts Drs. Matthew Drake and Nestor Molfino provide an overview of type 2 inflammation, the role of eosinophils in asthma and potential role in COPD, eosinophil-induced remodeling and eosinophil heterogeneity

•    Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management
Medical expert Dr. Geoffrey Chupp provides a disease overview of EGPA, its clinical manifestations, pathogenesis, diagnosis, differentiation, and management recommendations

•    Uncontrolled Asthma-Changing the Patient Experience
Medical expert Dr. Geoffrey Chupp provides insight into the challenges of coping with uncontrolled asthma, reviews the current treatment paradigms, and identifies ways to customize management of uncontrolled asthma by pairing the right medications with the right patients

Watch at: gskecongress.within3.com

______________________________________________________________________________

Clinical Data and Insights for Using a Biologic to Manage Severe Eosinophilic Asthma

Sponsored by GSK

Please follow the link for 3 short excerpts where medical experts Dr. Jacqueline Eghari-Sabet, Dr. Shahnaz Fatteh, and Dr. Yaron Goldman deliver case driven presentations to highlight the clinical features of Severe Eosinophilic Asthma and a biologic treatment. Each guest speaker will cover key aspects of severe patient types that may help determine when a biologic therapy could be an effective treatment option. Watch on-demand anytime.

Watch at: gskvideoresources.com


Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK